Interferon‑induced transmembrane protein 3 (IFITM3) is an antiviral membrane protein that also has emerging roles in modulating inflammatory pathways. While IFITM3 has been studied extensively for host antiviral defense, its role during severe systemic infections and in critical illness has been less clear. The authors set out to evaluate IFITM3 protein levels in respiratory and systemic compartments of critically ill patients to determine whether IFITM3 is associated with sepsis and pulmonary infection in the intensive care setting.
The study used two sample sets described as a BAL Cohort and a Critical Illness Cohort. BAL samples were obtained and processed to generate cell‑free, soluble BAL fluid. The BAL processing included centrifugation at 16,000×g to remove cellular debris prior to analysis. Plasma samples from critically ill patients and healthy donors were used to isolate circulating extracellular vesicles (EVs). Plasma EV preparations were protein normalized before analysis.
Soluble, cell‑free BAL fluid fractions were analyzed by immunoblot for IFITM3. For BAL quantification, IFITM3 levels were normalized to the total BAL volume obtained from each patient. Plasma EVs were isolated from the Critical Illness Cohort and healthy donors; EV protein content was normalized and then analyzed for IFITM3 by immunoblot. The authors note that sequential centrifugation of BAL samples did not yield sufficient EVs for EV‑specific analysis in the BAL cohort because of limited sample volume.
Analysis of cell‑free BAL demonstrated that IFITM3 levels were significantly higher in BAL from septic patients with pulmonary infections compared with control groups. BAL samples were processed to remove cell debris and equal volumes of cell‑free BAL were loaded for immunoblot analysis; IFITM3 quantification was normalized to BAL volume. These data indicate a local, lung‑compartment elevation of IFITM3 associated with pulmonary infection in critically ill, septic patients.
In plasma, circulating EV preparations from critically ill septic patients showed higher levels of IFITM3 compared with EVs from critically ill non‑septic patients and from healthy donors. Plasma EVs were protein normalized prior to immunoblot analysis. The detection of IFITM3 in plasma EVs implies a systemic presence of the protein within vesicular carriers during sepsis in critical illness.
The study reports several technical constraints documented by the authors. Limited BAL volumes prevented isolation of sufficient EVs from BAL for EV‑specific assays, so BAL IFITM3 data derive from soluble, cell‑free fluid rather than BAL EV preparations. The study design described in the source is observational and focused on protein detection; mechanistic roles of IFITM3 in host immune dysregulation or causality in sepsis were not established in this report. Additional methodological details, such as cohort sizes, patient demographics, timing of sampling relative to infection onset, and statistical analysis, were not provided in the abstract and figure legend supplied here.
These results provide the first evidence, according to the authors, linking elevated IFITM3 in respiratory and systemic compartments with sepsis‑associated inflammatory responses and with bacterial pulmonary infections in the ICU. The presence of IFITM3 in both cell‑free BAL fluid and in circulating plasma EVs suggests that IFITM3 may reflect localized lung inflammation and a concurrent systemic signal conveyed by EVs during severe infection. As an interferon‑induced antiviral protein that also interacts with inflammatory pathways, IFITM3 could serve as a biomarker of dysregulated immunity in sepsis or potentially influence host responses; however, functional or interventional data to support either role are not reported here.
The study identifies increased IFITM3 levels in cell‑free BAL fluid from septic patients with pulmonary infections and in plasma EVs from critically ill septic patients compared with critically ill non‑septic patients and healthy individuals. These observations link IFITM3 to sepsis‑related inflammatory responses and pulmonary infection in the intensive care setting. The findings warrant further investigation to define the mechanistic role of IFITM3 in sepsis, to evaluate its potential as a biomarker, and to determine whether EV‑associated IFITM3 contributes to systemic immune modulation during critical illness.